期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

半合成糖肽类抗生素的研究进展 被引量：5

Progress in Research on Semisynthetic Glycopeptide Antibiotics
原文传递
导出
摘要 综述了糖肽类抗生素的结构特征、作用机制、细菌耐药机制以及包括氨基、糖基、羧基、芳环等位点的化学修饰的研究进展,简介几种近年上市或进入Ⅲ期临床研究的半合成糖肽类抗生素。 The structural characteristics,antibacterial mechanisms of the glycopeptide antibiotics and bacterial resistance mechanisms as well as the advances of chemical modifications on amino,glucosyl,carboxyl,aromatic ring in the glycopeptide framework are reviewed,several semisynthetic glycopeptide antibiotics marketed or entered into phaseⅢ clinical trials in recent years are introduced.
作者 邵昌 周伟澄
机构地区 中国医药工业研究总院 上海医药工业研究院创新药物与制药工艺国家重点实验室
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2011年第5期378-387,共10页 Chinese Journal of Pharmaceuticals
基金 国家"重大新药创制"科技重大专项(2009ZX09301-007) 国家973计划(2010CB735600)
关键词 半合成糖肽类抗生素 特拉万星 奥利万星 达巴万星 综述 semisynthetic glycopeptide antibiotics telavancin oritavancin dalbavancin review
分类号 R9 [医药卫生—药学]
  • 相关文献

参考文献23

  • 1张鸽.注射用杀菌性糖肽类抗生素Telavancin[J].药学进展,2007,31(4):188-190. 被引量：2
  • 2杨敏婕,杨帆.新糖肽类抗生素dalbavancin[J].中国感染与化疗杂志,2006,6(2):140-143. 被引量：2
  • 3Kahne D,,Leimkuhler C,Lu W,et al.Glycopeptide andlipoglycopeptide antibiotics. Chemical Reviews . 2005
  • 4Birgand G.Glycopeptide resistant enterococci:What’’s theproblem. Curr Anaesthesia Critical Care . 2009
  • 5Nitanai Y,Kikuchi T,Kakoi K,et al.Crystal structures ofthe complexesbetween vancomycin and cell-wall precursoranalogs. Journal of Molecular Biology . 2009
  • 6Leung SS,Tirado-Rives J,Jorgensen WL.Vancomycinresistance:modeling backbone variants with D-Ala-D-Alaand D-Ala-D-Lac peptides. Bioorganic and Medicinal Chemistry . 2009
  • 7Judice JK,Fatheree PR,Lam BMT,et al.Glycopeptidederivatives and pharmaceutical compositions containing thesame. US,7723470 . 2010
  • 8Plattner JJ,Chu D,Mirchink EP,et al.N′-(α-aminoacyl)-and N′-α-(N-alkylamino)acyl derivatives of vancomycinand eremomycin.Ⅱ.Antibacterial activity of N′-(α-aminoacyl)-and N′-α-(N-alkylamino)acyl derivatives ofvancomycin and eremomycin. Journal of Antibiotics . 2007
  • 9Kim SJ,Schaefer J.Hydrophobic side-chain lengthdetermines activity and conformational heterogeneityof a vancomycin derivative bound to the cell wall ofStaphylococcus aureus. Biochemistry . 2008
  • 10Nagarajan R,Schabel AA,Occolowitz JL,et al.Synthesisand antibacterial evaluation of N-alkyl vancomycins. Japanese Journal of Antibiotics . 1989

二级参考文献12

  • 1Malabarba A,Goldstrein BP.Origin,structure,and activity in vitro and in vivo of dalbavancin[J].J Antimicrob Chemother,2005,55 (Suppl2):ii15-ii20.
  • 2Streit JM,Fritsche TR,Sader HS,et al.Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates[J].Diagn Microbiol Infect Dis,2004,48:137-143.
  • 3Streit JM,Sader HS,Fritsche TR,et al.Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens[J].Diagn Microbiol Infect Dis,2005,53:307-310.
  • 4Bozdogan B,Esel D,Whitener C,et al.Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center[J].J Antimicrob Chemother,2003,52:864-868.
  • 5Candiani G,Abbondi M,Borgonovi M,et al.In-vitro and in-vivo antibacterial activity of BI397,a new semi-synthetic glycopeptide antibiotic[J].J Antimicrob Chemother,1999,44:179-192.
  • 6Darouiche RO,Mansouri MD.Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo[J].J Infect,2005,50:206-209.
  • 7Dorr MB,Jabes D,Cavaleri M,et al.Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin,a semi-synthetic glycopeptide[J].J Antimicrob Chemother,2005,55 (Suppl 2):ii25-ii30.
  • 8Leighton A,Gottlieb AB,Dorr MB,et al.Tolerability,pharmacokinetics,and serum bactericidal activity of intravenous dalbavancin in healthy volunteers[J].Antimicrob Agents Chemother,2004,48:940-945.
  • 9Cavaleri M,Riva S,Valagussa A,et al.Pharmacokinetics and excretion of dalbavancin in the rat[J].J Antimicrob Chemother,2005,55 (Suppl 2):ii31-ii35.
  • 10Seltzer E,Dorr MB,Goldstein BP,et al.Once-weekly dalbavancin versus standard-of -care antimicrobial regimens for treatment of skin and soft-tissue infections[J].Clin Infect Dis,2003,37:1298-1303.

共引文献2

同被引文献30

引证文献5

二级引证文献6

中国医药工业杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部